⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12435317 | 0.79 | MAOA (0.42) | — | |
| SCHEMBL24816949 | 0.71 | SETD7 (0.48) | — | |
| SCHEMBL7051483 | 0.71 | — | — | |
| SCHEMBL26702 | 0.71 | — | — | |
| SCHEMBL22421086 | 0.69 | DRD2 (0.48) | — | |
| SCHEMBL18588177 | 0.69 | — | — | |
| SCHEMBL12705960 | 0.69 | DRD2 (0.54) | — | |
| SCHEMBL272823 | 0.69 | — | — | |
| SCHEMBL68353 | 0.69 | — | — | |
| SCHEMBL272822 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192801-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | claimed |
| US-20220389009-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GFB (ABC), LLC | 2022-12-08 | — | — | US | claimed |
| CN-114761000-A | Substituted 1, 6-naphthyridine inhibitors of CDK5 | 金翅雀生物公司 | 2022-07-15 | — | — | CN | claimed |
| CN-109923108-B | Pyridyl-substituted indole compounds | 百时美施贵宝公司 | 2022-04-29 | — | — | CN | claimed |
| EP-3298011-B1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2021-11-17 | — | — | EP | claimed |
| WO-2021067569-A1 | SUBSTITUTED 1, 6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GOLDFINCH BIO, INC. (US) | 2021-04-08 | — | — | WO | claimed |
| US-20180155340-A1 | QUINOLONE DERIVATIVES AS FGFR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2018-06-07 | — | — | US | claimed |
| EP-2994470-B1 | PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2018-04-18 | — | — | EP | claimed |
| EP-3298011-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2018-03-28 | — | — | EP | claimed |
| US-9630963-B2 | Quinolone derivatives as fibroblast growth factor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2017-04-25 | — | — | US | claimed |
| WO-2016191172-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2016-12-01 | — | — | WO | claimed |
| US-20160130268-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2016-05-12 | — | — | US | claimed |
| EP-1396491-A2 | 2-substituted 4,5-diaryl-imidazoles and their use as p38 MAP kinase inhibitors | Novartis AG (CH) | 2004-03-10 | — | — | EP | claimed |
| WO-2023192801-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20220389009-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GFB (ABC), LLC | 2022-12-08 | — | — | US | disclosed |
| EP-1396491-A2 | 2-substituted 4,5-diaryl-imidazoles and their use as p38 MAP kinase inhibitors | Novartis AG (CH) | 2004-03-10 | — | — | EP | disclosed |
| US-6300347-B1 | FOR THERAPY OF TUMOR NECROSIS FACTOR AND INTERLEUKIN-1 MEDIATED DISEASES SUCH AS RHEUMATOID ARTHRITIS AND DISEASES OF BONE METABOLISM, E.G. OSTEOPOROSIS | NOVARTIS AG (CH) | 2001-10-09 | — | — | US | disclosed |
| EP-0993456-A1 | 2-SUBSTITUTED 4,5-DIARYL IMIDAZOLES | Novartis AG (CH) | 2000-04-19 | — | — | EP | disclosed |
| WO-1999001449-A1 | 2-SUBSTITUTED 4,5-DIARYL IMIDAZOLES | NOVARTIS AG (CH) | 1999-01-14 | — | — | WO | disclosed |